Anna Maria Pertosa
University of Bologna
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anna Maria Pertosa.
Gastroenterology | 2009
Marco Domenicali; Paolo Caraceni; F. Giannone; Anna Maria Pertosa; Alessandro Principe; Andrea Zambruni; Franco Trevisani; Tiziano Croci; Mauro Bernardi
BACKGROUND & AIMS Endocannabinoids contribute to hemodynamic abnormalities of cirrhosis. Whether this favors renal sodium retention and ascites formation is unknown. We determined whether cannabinoid type 1 receptor antagonism prevents sodium retention and ascites formation in preascitic cirrhotic rats. METHODS Once renal sodium handling was impaired, rats with carbon tetrachloride-induced cirrhosis were randomized to receive either vehicle or rimonabant (3 [group 1] or 10 [group 2] mg x kg(-1) x day(-1)) for 2 weeks. Natriuresis, sodium intake, and sodium balance were measured daily. At the end of the protocol, systemic hemodynamics, renal blood flow, ascites volume, and liver fibrosis were assessed. RESULTS A significant reduction in ascites formation (group 1: 54%; group 2: 10%; vehicle: 90%) and volume (group 1: 1.6 +/- 0.3 mL; group 2: 0.5 mL; vehicle: 5.5 +/- 0.8 mL) occurred in treated rats. Rimonabant significantly improved sodium balance during week 2 (group 1: 0.98 +/- 0.08 mmol; group 2: 0.7 +/- 0.08 mmol; vehicle: 3.05 +/- 0.11 mmol). Both treated groups showed lower cardiac output and higher mean arterial pressure, peripheral vascular resistance, and renal blood flow (P < .05). Liver fibrosis was reduced in group 2 by 30% (P < .05 vs vehicle). Mean arterial pressure inversely correlated with sodium balance (R = -0.61; P = .003), but not with fibrosis score. CONCLUSIONS Rimonabant improves sodium balance and delays decompensation in preascitic cirrhosis. This is achieved though an improvement in systemic and renal hemodynamics, although it cannot be excluded that the antifibrotic effect of the drug may play a role.
Journal of Hepatology | 2009
Matteo Cescon; Rita Carini; Gian Luca Grazi; Paolo Caraceni; Elisa Alchera; Giorgio Gasloli; Matteo Ravaioli; F. Tuci; Chiara Imarisio; Caterina Dal Ponte; Anna Maria Pertosa; Mauro Bernardi; Antonio Daniele Pinna; Emanuele Albano
BACKGROUND/AIMS The efficacy of ischemic preconditioning (IPC) in preventing reperfusion injury in human liver transplants is still questioned. Phosphoinositide-3-kinase (PI3K) is essential for IPC development in rodent livers. This work investigates whether PI3K-dependent signals might account for the inconsistent responses to IPC of transplanted human livers. METHODS Forty livers from deceased donors were randomized to receive or not IPC before recovery. PI3K activation was evaluated in biopsies obtained immediately before IPC and 2 h after reperfusion by measuring the phosphorylation of the PI3K downstream kinase PKB/Akt and the levels of the PI3K antagonist phosphatase tensin-homologue deleted from chromosome 10 (PTEN). RESULTS IPC increased PKB/Akt phosphorylation (p = 0.01) and decreased PTEN levels (p = 0.03) in grafts, but did not significantly ameliorate post-transplant reperfusion injury. By calculating T(2h)/T(0) PKB/Akt phosphorylation ratios, 10/19 (53%) of the preconditioned grafts had ratios above the control threshold (IPC-responsive), while the remaining nine grafts showed ratios comparable to controls (IPC-non-responsive). T(2h)/T(0) PTEN ratios were also decreased (p < or = 0.03) only in IPC-responsive grafts. The patients receiving IPC-responsive organs had ameliorated (p < or = 0.05) post-transplant aminotransferase and bilirubin levels, while prothrombin activity was unchanged. CONCLUSIONS Impaired PI3K signaling might account for the variability in the responses to IPC of human grafts from deceased donors.
Journal of Hepatology | 2004
Paolo Caraceni; Cristina Bianchi; Marco Domenicali; Anna Maria Pertosa; Elisabetta Maiolini; Giovanna Parenti Castelli; Bruno Nardo; Franco Trevisani; Giorgio Lenaz; Mauro Bernardi
Digestive and Liver Disease | 2005
Marco Domenicali; Gianluigi Vendemiale; Gaetano Serviddio; Ignazio Grattagliano; Anna Maria Pertosa; Bruno Nardo; Alessandro Principe; Antonella Viola; Franco Trevisani; Emanuele Altomare; Mauro Bernardi; Paolo Caraceni
Journal of Surgical Research | 2006
Bruno Nardo; Paolo Caraceni; L. Puviani; Anna Maria Pertosa; Marco Domenicali; Milena Pariali; Graziella Angiolini; Pasquale Chieco; Franco Trevisani; Mauro Bernardi; Antonino Cavallari
Transplantation Proceedings | 2006
Bruno Nardo; L. Puviani; Paolo Caraceni; V. Pacilè; R. Bertelli; P. Beltempo; Giuseppe Cavallari; Pasquale Chieco; Milena Pariali; Anna Maria Pertosa; Graziella Angiolini; Marco Domenicali; Flavia Neri; D. Prezzi; M. Tsivian; Mauro Bernardi; Antonino Cavallari
Journal of Hepatology | 2005
Marco Domenicali; Paolo Caraceni; Alessandro Principe; Anna Maria Pertosa; Josefa Ros; Pasquale Chieco; Franco Trevisani; Wladimiro Jiménez; Mauro Bernardi
Journal of Hepatology | 2008
Marco Domenicali; Paolo Caraceni; Anna Maria Pertosa; F. Giannone; Alessandro Principe; Andrea Zambruni; Franco Trevisani; Mauro Bernardi
Journal of Surgical Research | 2005
Paolo Caraceni; Marco Domenicali; Anna Maria Pertosa; Elisabetta Maiolini; Ignazio Grattagliano; Alessandro Principe; Giuseppe Palasciano; Franco Trevisani; Mauro Bernardi
Digestive and Liver Disease | 2005
Marco Domenicali; Anna Maria Pertosa; B Cavalieri; Mg Perrelli; Alessandro Principe; J.C Cutrìn; Tiziano Croci; Mauro Bernardi; P. Caraceni